ArticlePloS one2017
Characterization of recombinant human lactoferrin N-glycans expressed in the milk of transgenic cows.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 61 citations in OpenAlex.
- Chemicals in cow milk and soy beverages: Neurotoxicity and neuroprotection.Advances in neurotoxicology · 2026Article
- Bioactive Peptides from Bovine Colostrum: Sources, Structures, and Biomedical Applications.Probiotics and antimicrobial proteins · 2026Review
- Optimizing Lactoferrin Isolation for Functional and Structural Integrity: A Molecular Insight.Molecules (Basel, Switzerland) · 2026Review
- Osteopontin: Its Properties, Recent Studies, and Potential Applications.International journal of molecular sciences · 2025Review
- Lactoferrin: Properties and Potential Uses in the Food Industry.International journal of molecular sciences · 2025Review
- The ferroform and glycoform landscape of human milk lactoferrin dissected through hybrid mass spectrometric approaches.Frontiers in nutrition · 2025Article
- Lactoferrin as a Versatile Agent in Nanoparticle Applications: From Therapeutics to Agriculture.Nanomaterials (Basel, Switzerland) · 2024Review
- Characterization of recombinant human lactoferrin expressed inThe Analyst · 2024Article
- Label-Free Liquid Chromatography-Mass Spectrometry Quantitation of RelativeInternational journal of molecular sciences · 2024Article
- Changes in the Immunology of Breast Milk From Obese or Overweight Women: a Brief Review.Cureus · 2024Review
- The Multifaceted Roles of Bovine Lactoferrin: Molecular Structure, Isolation Methods, Analytical Characteristics, and Biological Properties.Journal of agricultural and food chemistry · 2023Review
- Lactoferrin: neuroprotection against Parkinson's disease and secondary molecule for potential treatment.Frontiers in aging neuroscience · 2023Review
- Human Lactoferrin Synergizes with Etoposide to Inhibit Lung Adenocarcinoma Cell Growth While Attenuating Etoposide-Mediated Cytotoxicity of Human Endothelial Cells.Biomedicines · 2022Article
- Lactoferrin Decreases EnterotoxigenicPharmaceutics · 2022Article
- Plasmalemmal V-ATPase as a Potential Biomarker for Lactoferrin-Based Anticancer Therapy.Biomolecules · 2022Article
- Lactoferrin for COVID-19 prevention, treatment, and recovery.Frontiers in nutrition · 2022Review
- A Novel Human Recombinant Lactoferrin Inhibits Lung Adenocarcinoma Cell Growth and Migration with No Cytotoxic Effect on Normal Human Epithelial Cells.Archivum immunologiae et therapiae experimentalis · 2021Article
- Characterization of the regulatory 5'-flanking region of bovine mucin 2 (MUC2) gene.Molecular and cellular biochemistry · 2021Article
- Comparison of bovine milk oligosaccharides in native North European cattle breeds.International dairy journal · 2021Article
- Serum Protein N-Glycans in Colostrum and Mature Milk of Chinese Mothers.Journal of agricultural and food chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Lactoferrin (LF) is one of the most abundant bioactive glycoproteins in human milk. Glycans attached through N-glycosidic bonds may contribute to Lactoferrin functional activities. In contrast, LF is present in trace amounts in bovine milk. Efforts to increase LF concentration in bovine milk led to alternative approaches using transgenic cows to express human lactoferrin (hLF). This study investigated and compared N-glycans in recombinant human lactoferrin (rhLF), bovine lactoferrin (bLF) and human lactoferrin by Nano-LC-Chip-Q-TOF Mass Spectrometry. The results revealed a high diversity of N-glycan structures, including fucosylated and sialylated complex glycans that may contribute additional bioactivities. rhLF, bLF and hLF had 23, 27 and 18 N-glycans respectively with 8 N-glycan in common overall. rhLF shared 16 N-glycan with bLF and 9 N-glycan with hLF while bLF shared 10 N-glycan with hLF. Based on the relative abundances of N-glycan types, rhLF and hLF appeared to contain mostly neutral complex/hybrid N-glycans (81% and 52% of the total respectively) whereas bLF was characterized by high mannose glycans (65%). Interestingly, the majority of hLF N-glycans were fucosylated (88%), whereas bLF and rhLF had only 9% and 20% fucosylation, respectively. Overall, this study suggests that rhLF N-glycans share more similarities to bLF than hLF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.